Sign in
CompletedPhase 2

BCAAs in Concussion 2.0

Key facts

Who runs it
Akiva Cohen
Where
Philadelphia, United StatesSee the site
Trial code
Status
Completed
Phase
Phase 2
People taking part
17 people enrolled
Started
1 Apr 2025
Ended
1 Jul 2026
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • BCAA
  • Placebo
Record updated
3 September 2026

Who can take part

Age
11 years to 23 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Males and females,11 - 23 years of age
  • Weigh at least 40kg
  • Meeting concussion criteria for the American Congress of Rehabilitative Medicine
  • Present within 4 days of injury
  • Post-menarchal females must have a negative urine pregnancy test and must use an acceptable method of contraception
  • Informed consent by the participant, or for participants <18 years old both informed consent by a parent/guardian and child assent

Who cannot take part

  • Prior concussion or TBI within 90 days
  • Any investigational drug use within 30 days prior to enrollment
  • Known history of maple syrup urine disease or known family history of maple syrup urine disease
  • Hypersensitivity to any ingredient in the active or placebo products
  • Evidence of moderate or severe Traumatic Brain Injury (TBI), including Glasgow Coma Scale (GCS) <13, TBI requiring hospital admission, or TBI requiring neurosurgical intervention
  • Participants who are pregnant, planning on becoming pregnant during the study duration, or breastfeeding
  • Non-English speaking participants or parent/guardian

Where in United States

  • Children's Hospital of PhiladelphiaPhiladelphia, United States

About the trial

What the trial wants to find out

This study is a randomized, placebo-controlled, double-blinded, therapeutic exploratory clinical trial of branched chain amino acids (BCAAs) in the treatment of concussion. The aim of the study is to determine whether administration of high-dose BCAAs compared to placebo promotes concussion recovery.

The 2 groups in the trial

  • Drug: Branched Chain Amino AcidsTreatment being tested

    The three BCAAs will be combined together and dissolved into a flavored solution.

    Treatment: BCAA

  • PlaceboPlacebo, for comparison

    The placebo solution will have similar taste, texture, consistency and appearance as the BCAA solution.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
HIT HEADS 2.0: Head Injury Treatment: A Randomized, Placebo-controlled, Double-blinded, Therapeutic Clinical Trial of Branched Chain Amino Acids (BCAAs) in the Treatment of Concussion
Record updated
3 September 2026